A unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThr

Project Information

RECOFIB

Grant agreement ID: 190183175

DOI

10.3030/190183175

Project terminated on 2 February 2024

EC signature date 31 August 2022

Start date 1 April 2022

End date 31 December 2023

Funded under

• The European Innovation Council (EIC)

Total cost

€ 4 495 826,25

EU contribution

€ 2 500 000,00

Coordinated by

FIBRIANT BV
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (2)

Journal of Thrombosis and Haemostasis

Author(s): Oscar Negrón, Miranda Weggeman, Jos Grimbergen, Emily G. Clark, Sara Abrahams, Woosuk S. Hur, Jaap Koopman, and Matthew J. Flick
Published in: J Thromb Haemost., Issue S1538-7836(23)00250-7, 2023, ISSN 1538-7933
Publisher: Wiley
DOI: 10.1016/j.jtha.2023.03.019

Interplay of fibrinogen αEC globular domains and factor XIIIa cross-linking dictates the extensibility and strain stiffening of fibrin networks

Author(s): Cristina Martinez-Torres, Jos Grimbergen , Jaap Koopman, Gijsje H Koenderink
Published in: Journal of Thrombosis and Haemostasis, 2024, ISSN 1538-7836
Publisher: Elsevier
DOI: 10.1016/j.jtha.1023.10.025

Intellectual Property Rights

Patent (2)

THERAPEUTIC USES OF FIBRINOGEN GAMMA PRIME VARIANTS

Application/Publication number: 20 19060546
Date: 2019-04-24
Applicant(s): FIBRIANT BV

FIBRINOGEN AS ADJUVANT FOR ANTIMICROBIAL AGENTS AND THERAPY

Application/Publication number: 20 20079970
Date: 2020-10-23
Applicant(s): FIBRIANT BV